NVX-CoV2373 is being developed by US-based Novavax Inc. (NVAX).Current Status: NVX-CoV2373 is under a phase I/II trial. Mode of Action: NVX-CoV2373 contains a recombinant version of SARS-CoV-2's spike protein nanoparticles and the Company's proprietary Matrix-M adjuvant. This vaccine belongs to the category subunit vaccine.Unlike traditional vaccines, which contain the entire pathogens that are killed or weakened, the subunit vaccines include only the components, or antigens, that best stimulate the immune system.Next Milestone:The preliminary immunogenicity and safety results from the phase I portion of the trial are expected in July 2020. If the results are promising, the phase II portion of the trial will be initiated quickly.